Cite
HARVARD Citation
Zabaleta, N. et al. (2018). CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I. Nature communications. 9 (1), pp. 1-9. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Zabaleta, N. et al. (2018). CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I. Nature communications. 9 (1), pp. 1-9. [Online].